Skip to main content

Mission Investments


The Australian Government and Mission Funding Partners have awarded a total of $50.16 million to Medical Research Future Fund (MRFF) initiatives under the Mission:



Commitment (million)

Zero Childhood Cancer Initiative

University of New South Wales


Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG)

Monash University


Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG)

Monash University (co-funded with Financial Markets Foundation for Children, the Robert Connor Dawes Foundation and Carrie’s Beanies 4 Brain Cancer)


Cooperative Trials Group for Neuro-Oncology (COGNO)

University of Sydney


COZMOS: Phase I/Ib trial of COmbined 5'-aZacitidine and carboplatin for recurrent/refractory paediatric brain and solid tuMOurs

Monash University (co-funded with Carrie’s Beanies 4 Brain Cancer)


SJ-ELiOT: St Jude - Phase 1 Evaluation of LY2606368, molecularly-targeted CHK1/2i Therapy, in combination with cyclophosphamide or gemcitabine for children and adolescents with refractory or recurrent medulloblastoma brain tumours

Monash University (co-funded with Carrie’s Beanies 4 Brain Cancer)


MAGMA: Multi-Arm GlioblastoMa Australasia Trial

University of Sydney (co-funded with Carrie’s Beanies 4 Brain Cancer and the Mark Hughes Foundation)


PICCOG: PARP and Immune Checkpoint inhibitor COmbination for relapsed IDH-mutant high-grade Glioma

University of Sydney


FET-PET in Glioma (FIG Study) 

La Trobe University


LUMOS: Low & intermediate grade glioma umbrella study of molecular guided therapies

University of Sydney


Role of the NKp44-PDGF-DD axis in glioblastoma

University of Melbourne


PARC: A Phase I/II study evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) relapsed/refractory cancers of children and young adults

Monash University


Targeted invadapodia to treat glioblastomas

University of Melbourne


BRAIN: Brain cancer Rehabilitation, Assessment, Intervention of survivor Needs

University of Sydney


A new nurse-led intervention to re-engage childhood brain cancer survivors

University of New South Wales


Responding to need: technology-enhanced brain cancer survivorship

University of Melbourne


MET-MED Trial: A phase III randomised double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients

Monash University


CONNECT 1903: A pilot and surgical study of larotrectinib for disease control in children with newly-diagnosed high-grade glioma with NTRK fusion

Monash University


LOGGIC: A phase III, randomised international multi-centre trial for LOw Grade Glioma In Children and adolescents

University of New South Wales


LUMOS: Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS

University of Sydney


GLIMMER: Glioma Liquid biopsy and Multiomic-Monitoring Enabled Research platform

The Walter and Eliza Hall Institute of Medical Research


A new targeted combination therapy with matched biomarker to treat intractable glioblastoma

University of New South Wales


“Off-the-shelf” CAR-T cell immunotherapy for brain cancer

The Council of the Queensland Institute of Medical Research


Supporting Australian Brain Cancer Research with an integrated network of platforms

University of Sydney



In addition to co-funding MRFF opportunities, Mission Funding Partners have committed $59.54 million in initiatives under the Mission that are funded and managed independently.

Page last updated on 16 May 2023